Navigation Links
ASCO Results: Oncologists Rank Genentech Number One

SAN MATEO, Calif., June 10 /PRNewswire/ -- When asked which company stood out at last week's ASCO conference in Chicago, oncologists cited Genentech at the top of the list, according to AlphaDetail, Inc., a leader in oncology primary market research and influence network mapping solutions to the Global Life Sciences Industry.

In a brief on-line survey of 103 oncologists conducted soon after the close of the conference, AlphaDetail was able to gather some interesting feedback about oncologist perceptions of the meeting. The ASCO Annual Meeting attracts more than 30,000 attendees and is considered the premier educational and scientific event in the oncology community.

-- 60% of US oncologists attended the ASCO Annual Meeting.

-- Oncologists rate Genentech #1 on overall image in oncology and cite it

as the top company that stood out above the others at ASCO.

-- Oncologists cite the following as the three most important pieces of

data presented at ASCO:

-- KRAS status predicts response to first-line cetuximab for

metastatic colorectal cancer.

-- Erbitux (cetuximab) + platinum-based chemotherapy extends overall

survival in NSCLC vs. chemotherapy alone.

-- Zometa (zoledronic acid) increases survival for premenopausal

patients who received adjuvant endocrine therapy for early breast


To learn more about this study, please contact Bob Latshaw at or (215) 259-5601.

About AlphaDetail, Inc.:

At AlphaDetail, we have an unparalleled commitment to our clients. We are a full-service primary market research firm, with a particular emphasis in large and complex quantitative studies for the global healthcare community. AlphaDetail is built on one of the industry's strongest foundations that includes a large team of exceptional analytical specialists, the industry's leading technology platform and a flexible approach to research that helps us to answer our client's most challenging questions.

SOURCE AlphaDetail, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VNUS Medical Technologies Reports First-Quarter 2008 Results: 21% growth in Net Revenues and 51% Growth in Unit Sales
2. Oncologists Want to See Significant Improvement in Overall Survival Before Adopting Targeted Polytherapy in a First-Line Setting
3. Thomas W. Burke, MD, Elected 40th President of the Society of Gynecologic Oncologists
4. Amgen and Genentech Brace Themselves for Heavy Pressure From Biogenerics Manufacturers
5. Pfizer, Genentech, Amgen, Bayer, Wyeth, Abbott, Merck and Additional Leading Pharmaceutical Companies Participating During ExL Pharmas Fall Line Up!
6. Sangamo BioSciences Announces Expansion of Research and License Agreement With Genentech for ZFP Technology for Protein Pharmaceutical Production
7. BioWa Announces Expansion of License Agreement with Genentech for BioWas POTELLIGENT(R) Technology
8. Option to Develop Exelixis Compound Exercised By Genentech
9. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
10. The neural basis of number sense in young infants
11. BioSpace Career Fair in San Diego Draws Record Number of Bioscience Candidates
Post Your Comments:
(Date:11/27/2015)... November 27, 2015 ... popularity of companion diagnostics is one of ... market with pharmaceutical companies and diagnostic manufacturers ... tests. . --> ... report on global cancer biomarkers market spread ...
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE MKT: ... adopted a stockholder rights plan (Rights Plan) in an ... loss carryforwards (NOLs) under Section 382 of the Internal ... --> PharmAthene,s use of its NOLs could be ... as defined in Section 382 of the Code. In ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
Breaking Biology Technology:
(Date:11/10/2015)... 10, 2015  In this report, the ... of product, type, application, disease indication, and ... report are consumables, services, software. The type ... biomarkers, efficacy biomarkers, and validation biomarkers. The ... diagnostics development, drug discovery and development, personalized ...
(Date:11/2/2015)... Calif. , Nov. 2, 2015  SRI International ... million to provide preclinical development services to the National ... contract, SRI will provide scientific expertise, modern testing and ... variety of preclinical pharmacology and toxicology studies to evaluate ... --> The PREVENT Cancer Drug Development Program ...
(Date:10/29/2015)... , Oct. 29, 2015  Connected health pioneer, ... driving the explosion of technology-enabled health and wellness, and ... new book, The Internet of Healthy Things ... sensors or smartphones even existed, Dr. Kvedar, vice president, ... of health care delivery, moving care from the hospital ...
Breaking Biology News(10 mins):